Department of Pharmaceutical Biochemistry, Faculty of Pharmacy, Medical University of Gdansk, Debinki 1, 80-211 Gdansk, Poland.
Obesity and Metabolism Group, Biomedical Research Institute of Murcia (IMIB-Arrixaca), 30120 Murcia, Spain.
Int J Mol Sci. 2021 Jun 27;22(13):6900. doi: 10.3390/ijms22136900.
Non-alcoholic fatty liver disease (NAFLD) is a major public health problem worldwide. NAFLD (both simple steatosis and steatohepatitis) is characterized by alterations in hepatic lipid metabolism, which may lead to the development of severe liver complications including cirrhosis and hepatocellular carcinoma. Thus, an exhaustive examination of lipid disorders in the liver of NAFLD patients is much needed. Mass spectrometry-based lipidomics platforms allow for in-depth analysis of lipid alterations in a number of human diseases, including NAFLD. This review summarizes the current research on lipid alterations associated with NAFLD and related complications, with special emphasis on the changes in long-chain and short-chain fatty acids levels in both serum and liver tissue, as well as in the hepatic expression of genes encoding the enzymes catalyzing lipid interconversions.
非酒精性脂肪性肝病(NAFLD)是全球范围内的一个主要公共卫生问题。NAFLD(单纯性脂肪变性和脂肪性肝炎)的特征是肝脂质代谢的改变,这可能导致严重的肝脏并发症的发展,包括肝硬化和肝细胞癌。因此,非常需要对 NAFLD 患者的肝脏脂质紊乱进行详尽的检查。基于质谱的脂质组学平台允许对包括 NAFLD 在内的许多人类疾病中的脂质变化进行深入分析。本综述总结了与 NAFLD 相关的脂质变化及其相关并发症的最新研究进展,特别强调了血清和肝组织中长链和短链脂肪酸水平以及催化脂质相互转化的酶的基因在肝组织中的表达变化。